December 4, 2024 – OrthoSpineNews – Thomas Turgeon, MD, Associate Professor, Max Rady College of Medicine, recently presented updated Canadian data using the Reverse Hip Replacement System (Reverse HRS) during a plenary session at the 2024 Orthopedic Summit.
Dr. Turgeon presented up to date data from the Canadian trial using the Reverse HRS. The presentation reported on 65 patients who have reached the five-year mark, 2 years, and six-month post-op mark. The presentation included data on patients who had augmented screw fixation of the acetabular cup and a group that did not have screw fixation. A cohort of these patients surpassed 2 years, and a portion surpassed 1 year and six months.
“To date the radio-stereometric analysis of patients with and without screw fixation confirms they are all staying well within the published safe zones for femoral and acetabular migration,” said Dr. Turgeon. “These data confirm that the Reverse HRS implant appears to have an excellent fixation to bone, even out as far as five years.”
The Reverse HRS is a Metal-on-Polyethylene reverse geometry hip prosthesis designed to improve stability at extended ranges of motion and reduce the risk of dislocation. Like most conventional systems, the Reverse HRS consists of a femoral stem, an acetabular cup and a cobalt-chrome ball that articulates within a polyethylene liner. Unlike existing total hip replacement systems, the ball is placed on a trunnion within the acetabular cup instead of the femoral stem, and the polyethylene liner is attached to a femoral cup, which then attaches to the femoral stem, as opposed to the polyethylene liner being attached to the acetabular cup.
“Another main take-away from this presentation is that the Reverse HRS is behaving very much like a standard hip replacement device, and it seems to be more forgiving from a positioning perspective based on its inherent mechanical stability. Consequently, it could very easily play a strong role for patients with spinal-pelvic issues,” explains Dr. Turgeon. “Also, with developmental dysplasia that can have unusual geometry in terms of version and inclination, the Reverse HRS may be left in the more native position and still have the stability of the device compared to traditional bearings.”
In addition to these Canadian data, the HIT Reverse HRS, a multi-centered FDA-approved Investigational Device Exemption (IDE) study is being conducted in the U.S. to determine the safety and effectiveness of the HIT Reverse HRS in Primary Total Hip Arthroplasty (THA). This registrational study will assess safety through the collection of device-related adverse events and patient quality of life metrics. Effectiveness will be evaluated using clinical, radiologic, and patient-reported outcomes.
